Valeant Pharmaceuticals International, Inc. and Medicis Pharmaceutical Corporation have announced a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44.00 per share in cash.
The transaction values Medicis’ common stock at approximately $2.6 billion and is expected to close in the first half of 2013. Latham & Watkins LLP represents Medicis in the transaction with a corporate deal team led by partners Charles Ruck in Orange County, CA, Wesley Holmes in New York and Joshua Dubofsky in Silicon Valley, with associates Daniel Rees and Jason Liljestrom in Orange County. Advice was also provided on antitrust matters by partner Michael Egge with associate Jason Cruise in Washington D.C.: on benefits and compensation matters by partner Jim Barrall in Los Angeles with associate Carol Samaan in Orange County; on litigation matters by partners David Schindler in Los Angeles and Michele Johnson in Orange County; on regulatory matters by partner John Manthei with associate Elizabeth Richards in Washington D.C.; on intellectual property matters by partner Judith Hasko in Silicon Valley; on environmental matters by partner Christopher Norton in Orange County; and on tax matters by partner Nicholas DeNovio in Washington D.C.
Related Posts:
- Latham & Watkins Advises Quest Software in its Acquisition by Dell for $2.4 Billion
- Latham & Watkins – Lucasfilm Advised in Its US$4.05 Billion Acquisition by The Walt Disney Company
- Latham & Watkins Advises Suburban in Inergy Retail Propane Acquisition
- Weil Advises Applied Materials in $29 Billion Merger with Tokyo Electron
- Latham – Realty Income Corporation Advised in $2.95 Billion Acquisition of American Realty Capital Trust
